Lexaria Bioscience closed at $4.07 on Nov 4, up 0.99%, 95.4% below its 52-week closing high. Volume of 32.3K shares was 0.57× its 20-day average (below normal).
Split-adjusted performance: +25.6% over one month, -59.8% over six months, -73.9% over one year.
Short interest was 255.8K shares at the Oct 15 settlement, down 6.8% from the prior report (16.0% of float, 3.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LEXXLexaria Bioscience | $4.07 | +0.99% | −59.8% | −100.0% | — | — | $8.6M | |
| MBRXMoleculin Biotech | $8.46 | +1.93% | −82.9% | — | — | — | $8.6M | Compare |
| TOVXTheriva Biologics | $0.1900 | +4.40% | −50.3% | — | — | — | $8.7M | Compare |
| GTBPGT Biopharma | $4.84 | −8.16% | −51.9% | — | — | — | $8.7M | Compare |
| LTRNLantern Pharma | $0.5866 | −2.61% | −72.6% | — | — | — | $8.8M | Compare |
| MTVAMetaVia | $1.34 | +6.35% | −4.3% | — | — | — | $8.8M | Compare |
| ACTUActuate Therapeutics | $0.3699 | +5.69% | −87.6% | — | — | — | $8.9M | Compare |
| VTGNVistagen Therapeutics | $0.1843 | +9.70% | −69.8% | +504.9% | −882.8% | — | $8.2M | Compare |
| CURXCuranex Pharmaceuticals | $5.80 | −6.30% | −17.7% | — | — | — | $9.1M | Compare |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
